Summary
The aim was to study the frequency and appearance of cytoplasmic islet cell antibodies in relation to impairment of insulin secretory capacity and some clinical characteristics in a representative group of middle-aged (45–64 years) patients with Type 2 (non-insulin-dependent) diabetes mellitus (70 male, 63 female) at the time of diagnosis and at five-year follow-up. Non-diabetic control subjects (62 male, 82 female) were similarly examined at five-year intervals. At the baseline five out of 133 (3.8%) diabetic patients were positive for conventional and four (3.0%) for complement-fixing islet cell antibodies. Ten patients had become positive by the second screening for conventional antibodies and six for complement-fixing antibodies, but none showed negative conversion. Two non-diabetic subjects (1.5%) became antibody positive during the follow-up. Insulin treatment was started during the follow-up for four out of 15 (27%) conventional antibody positive and for one out of 121 (0.8%) antibody negative diabetic patients (p=0.001). The sensitivity of the positive conventional and complement-fixing antibody for identifying patients who developed an impairment of insulin secretory capacity (post-glucagon C-peptide ≦0.60nmol/l at 5-year) was 75%. The respective specificity was 90% and the positive predictive values were highest in the case of high positivity (50%). The negative predictive value of antibody positivity was close to 100%. In conclusion, islet cell antibody positivity in patients classified as Type 2 was persistent during the follow-up and predicted the future development of insulin deficiency especially in those patients with high or increasing antibody titres.
Article PDF
Similar content being viewed by others
References
Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D (1986) Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes. Diabetes Care 9: 129–133
Irvine WJ, McCallum CJ, Gray RS, Campbell CJ, Duncan LJP, Farquhar JW, Vaughan H, Morris PJ (1977) Pancreatic islet-cell antibodies in diabetes correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes 26: 138–147
Groop LC, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent Type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 35: 237–241
Lendrum R, Walker G, Cudworth AG, Theophanides C, Pyke DA, Bloom A (1976) Islet cell antibodies in diabetes mellitus. Lancet II: 1273–1276
Pujol-Borrell R, Richart C, Martin C, Martinez-Vacquez JM, Bottazzo GF (1978) Islet cell antibodies in Spanish diabetics. Lancet I: 268–269
Madsbad S, Bottazzo GF, Cudworth AG, Dean BM, Faber OK, Binder C (1980) Islet-cell antibodies and beta-cell function in insulin-dependent diabetics. Diabetologia 18: 45–47
Mustonen A, Knip M, Huttunen N-P, Puukka R, Käär M-L, Åkerblom HK (1984) Evidence of delayed beta-cell destruction in Type 1 (insulin-dependent) diabetic patients with persisting complement-fixing islet cell antibodies. Diabetologia 27: 421–426
Bruining GJ, Molenaar J, Tuk CW, Lindeman J, Bruining HA, Marner B (1984) Clinical time-course and characteristics of islet cell cytoplasmic antibodies in childhood diabetes. Diabetologia 26: 24–29
DelPrete GF, Betterle C, Padovan D, Erle G, Toffolo A, Bersahi G (1977) Incidence and significance of islet-cell autoantibodies in different types of diabetes mellitus. Diabetes 26: 909–915
Jennings AM, Spencer KM, Dean BM, Wilson RM, Bottazzo GF, Ward JD (1989) Islet cell antibodies and insulin autoantibodies in patients treated with oral hypoglycaemic agents. Diab Med 6: 434–439
Rodger B, Whittingham S, Martin FIR, Hawkins BR, Dawkins RL, Welborn TA (1980) A population survey of pancreatic islet cell antibodies. Clin Exp Immunol 39: 125–129
Notsu K, Oka N, Note S, Nabeya N, Kuno S, Sakurami T (1985) Islet cell antibodies in the Japanese population and subjects with Type 1 (insulin-dependent) diabetes. Diabetologia 28: 660–662
WHO Expert Committee (1980) Second report on diabetes mellitus. Geneva, World Health Organization. (Technical Report Series 646)
Uusitupa M, Siitonen O, Aro A, Pyörälä K (1985) Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged newly diagnosed Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 28: 22–27
Korhonen T, Uusitupa M, Aro A, Kumpulainen T, Siitonen O, Voutilainen E, Pyörälä K (1987) Efficacy of dietary instructions in newly diagnosed non-insulin-dependent diabetic patients. Comparison of two different patient education regimens. Acta Med Scand 222: 323–331
Faber OK, Binder C (1977) C-peptide response to glucagon: a test for the residual B-cell function in diabetes mellitus. Diabetes 26: 605–610
Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet II: 1279–1282
Bottazzo GF, Dean BM, Gorsuch AN, Cudworth AG, Doniach D (1980) Complement-fixing islet cell antibodies in type 1 diabetes: possible monitors of active beta-cell damage. Lancet I: 668–672
Karjalainen JK (1990) Islet cell antibodies as predictive markers for IDDM in normal children with a high background incidence of the disease. Diabetes 39: 1144–1150
Bonifacio E, Dawkins RL, Lernmark Å (1987) Immunology and Diabetes Workshops. Report on the Second International Workshop on the Standardisation of cytoplasmic islet cell antibodies. Diabetologia 30: 273
Uusitupa M (1983) Coronary heart disease and left ventricular performance in newly diagnosed non-insulin-dependent diabetics. Publications of the University of Kuopio. Series Original Reports 6 Kuopio (Dissertation)
Bellis A, Bizzarro A, Iacono G, Marfella A, Russo M, Cacciatore L (1988) Islet cell antibodies and serum neopterin levels in Type 2 (non-insulin-dependent) diabetes: a 2-year retrospective study. Diabetologia 31: 125 (Abstract)
Spencer KM, Tarn AC, Dean BM, Lister J, Bottazzo GF (1984) Fluctuating islet-cell auto-immunity in unaffected relatives of patients with insulin-dependent diabetes. Lancet I: 764–766
Srikanta S, Ganda OP, Jackson RA, Bring SJ, Fleischnick E, Yunis E, Alper C, Soeldner JS, Eisenbarth GS (1984) Pre-Type 1 (insulin-dependent) diabetes: common endocrinological course despite immunological and immunogenetic heterogeneity. Diabetologia 27: 146–148
Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K (1987) Time course of islet cell antibodies and B-cell function in non-insulin-dependent stage of type 1 diabetes. Diabetes 36: 510–517
Groop L, Miettinen A, Groop P-H, Meri S, Koskimies S, Bottazzo GF (1988) Organ-specific autoimmunity and HLA-DR antigens as markers for B-cell destruction in patients with type II diabetes. Diabetes 37: 99–103
Lendrum R, Walker G, Gamble DR (1975) Islet-cell autoantibodies in juvenile diabetes mellitus of recent onset. Lancet I: 880–883
Eisenbarth GS (1986) Type 1 diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360–1368
Karjalainen J, Salmela P, Ilonen J, Surcel H-M, Knip M (1989) A comparison of childhood and adult Type 1 diabetes mellitus. N Engl J Med 320: 881–886
Lev-Ran A, Hill LR (1987) Different body-fat distributions in IDDM and NIDDM. Diabetes Care 10: 491–494
Gray RS, Irvine WJ, Cameron EHD, Duncan LJP (1980) Glucose and insulin responses to oral glucose in non-insulin-dependent diabetics with and without the islet cell antibody. Diabetes 29: 312–316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niskanen, L., Karjalainen, J., Sarlund, H. et al. Five-year follow-up of islet cell antibodies in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34, 402–408 (1991). https://doi.org/10.1007/BF00403178
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403178